N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 ClinicalTrials.gov

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

Sponsor: Verve Therapeutics, Inc. • ClinicalTrials.gov ID: NCT06164730

Registry updated: 2026-09-02
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.

Interventions

  • VERVE-102 (Drug)
    Intravenous (IV) infusion

Eligibility criteria

Inclusion Criteria: * Diagnosis of HeFH or premature CAD Exclusion Criteria: * Homozygous familial hypercholesterolemia * Active or history of chronic liver disease * Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe * Clinically significant or abnormal laboratory values as defined by the protocol

Conditions

Heterozygous Familial Hypercholesterolemia Premature Coronary Heart Disease

Locations

  • Clinical Study Center — Dothan, Alabama, United States
  • Clinical Study Center — Pomona, California, United States
  • Clinical Study Center — Boca Raton, Florida, United States
  • Clinical Study Center — Jacksonville, Florida, United States
  • Clinical Study Center — Winter Park, Florida, United States
  • Clinical Study Center — Indianapolis, Indiana, United States
  • Clinical Study Center — High Point, North Carolina, United States
  • Clinical Study Center — Philadelphia, Pennsylvania, United States
  • Clinical Study Center — DeSoto, Texas, United States
  • Clinical Study Center — Renton, Washington, United States
  • Clinical Study Center — Adelaide, Australia
  • Clinical Study Center — Melbourne, Australia
  • Clinical Study Center — Sydney, Australia
  • Clinical Study Center — Chicoutimi, Canada
  • Clinical Study Center — Hamilton, Canada
  • Clinical Study Center — Montreal, Canada
  • Clinical Study Center — Québec, Canada
  • Clinical Study Center — Toronto, Canada
  • Clinical Study Center — Vancouver, Canada
  • Clinical Study Center — Rehovot, Israel
  • Clinical Study Center — Christchurch, New Zealand
  • Clinical Study Center — Birmingham, United Kingdom
  • Clinical Study Center — Cambridge, United Kingdom
  • Clinical Study Center — Edinburgh, United Kingdom
  • Clinical Study Center — London, United Kingdom
  • Clinical Study Center — Manchester, United Kingdom
  • Clinical Study Center — Nottingham, United Kingdom
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record